Literature DB >> 30236620

Clickable conjugates of bile acids and nucleosides: Synthesis, characterization, in vitro anticancer and antituberculosis studies.

Devesh S Agarwal1, Vagolu Siva Krishna2, Dharmarajan Sriram2, Perumal Yogeeswari2, Rajeev Sakhuja3.   

Abstract

A series of clickable bile acid-nucleosides conjugates linked directly or via amino acid linker were synthesized, and characterized by spectroscopic techniques such as 1H NMR, 13C NMR, FT-IR, HRMS and HPLC. The synthesized compounds 6a-p were screened for their in vitro anticancer property against a panel of three cancer cell lines (PC-3, MCF-7, IMR-32). In addition, the synthesized derivatives were also tested for their antimycobacterial activity against Mycobacterium tuberculosis H37Rv (ATCC 27294 strain). Among the screened compounds, cholic acid-uridine clicked conjugate (6c), and cholic acid-uridine clicked conjugate liked via phenylalanine moiety (6m) were found to be most active against MCF-7 and IMR-32 exhibiting an IC50 value of 8.084 and 8.71 µM, respectively. The antimycobacterial study of the synthesized conjugates revealed all the conjugates to be active with MIC values in the range of 4.09-15.41 µM. Deoxycholic acid-adenosine clicked conjugate (6b) showed most promising antituberculosis property with MIC value of 4.09 µM. Most of the synthesized conjugates were found to be safe at 50 µM against normal human embryonic kidney (HEK 293 T) cell line.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Anticancer; Antimycobacterial; Bile acid; Nucleosides; Triazoles

Mesh:

Substances:

Year:  2018        PMID: 30236620     DOI: 10.1016/j.steroids.2018.09.006

Source DB:  PubMed          Journal:  Steroids        ISSN: 0039-128X            Impact factor:   2.668


  1 in total

Review 1.  Bile Acid Conjugates with Anticancer Activity: Most Recent Research.

Authors:  Maria Luisa Navacchia; Elena Marchesi; Daniela Perrone
Journal:  Molecules       Date:  2020-12-23       Impact factor: 4.411

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.